Inhibikase Therapeutics, Inc. SEC filings IKT
Inhibikase Therapeutics, Inc. has 368 filings in SEC EDGAR's recent list, going back to Aug 31, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 11, 2026 | — |
| S-8 | Employee stock plan registration | Mar 26, 2026 | — |
| 424B5 | Prospectus supplement | Dec 19, 2025 | — |
| 424B5 | Prospectus supplement | Nov 21, 2025 | — |
| 424B5 | Prospectus supplement | Nov 20, 2025 | — |
| S-3 | Shelf registration | Jun 20, 2025 | — |
| S-8 | Employee stock plan registration | Mar 27, 2025 | — |
| S-8 | Employee stock plan registration | Feb 4, 2025 | — |
| S-3 | Shelf registration | Jan 10, 2025 | — |
| 424B3 | Prospectus | Dec 5, 2024 | — |
| S-3/A | Filing | Dec 3, 2024 | — |
| S-3 | Shelf registration | Nov 18, 2024 | — |
| 424B3 | Prospectus | Jun 27, 2024 | — |
| S-1 | Registration statement | Jun 18, 2024 | — |
| 424B5 | Prospectus supplement | May 22, 2024 | — |
| 424B5 | Prospectus supplement | May 20, 2024 | — |
| S-1/A | Amended registration statement | May 9, 2024 | — |
| S-1/A | Amended registration statement | May 9, 2024 | — |
| S-1/A | Amended registration statement | Apr 29, 2024 | — |
| S-1/A | Amended registration statement | Apr 25, 2024 | — |
| S-1 | Registration statement | Apr 19, 2024 | — |
| 424B5 | Prospectus supplement | Feb 1, 2024 | — |
| 424B3 | Prospectus | Apr 4, 2023 | — |
| POS AM | Filing | Mar 31, 2023 | — |
| 424B3 | Prospectus | Feb 8, 2023 | — |
| S-1 | Registration statement | Feb 2, 2023 | — |
| 424B5 | Prospectus supplement | Jan 27, 2023 | — |
| 424B5 | Prospectus supplement | May 17, 2022 | — |
| S-3 | Shelf registration | Feb 7, 2022 | — |
| S-8 | Employee stock plan registration | Sep 15, 2021 | — |
| 424B4 | Prospectus | Jun 17, 2021 | — |
| S-1 | Registration statement | Jun 11, 2021 | — |
| 424B4 | Prospectus | Dec 28, 2020 | — |
| S-1MEF | Filing | Dec 22, 2020 | — |
| S-1/A | Amended registration statement | Dec 4, 2020 | — |
| S-1/A | Amended registration statement | Nov 3, 2020 | — |
| S-1/A | Amended registration statement | Oct 16, 2020 | — |
| S-1/A | Amended registration statement | Sep 30, 2020 | — |
| S-1/A | Amended registration statement | Sep 15, 2020 | — |
| S-1 | Registration statement | Jul 23, 2020 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750149
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.